Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. June 14, 2018. Phil Pontikos.

Executive Summary

US FDA is concerned about the large number of recalls initiated by device-makers and is urging firms to take a close look at their quality systems to determine why troublesome products make it to market in the first place. See what the agency's national device expert, Phil Pontikos, said about it here.

"From our perspective, what we see is that firms can identify the cause – or causes – of a failure, and then engage in CAPA [corrective and preventive action] activities. But firms also need to ask themselves a big question: 'Why did the quality system that we put in place fail us so we couldn't figure [the problem] out before we released it?'" –Phil Pontikos, national device expert, US FDA

Click here for a free trial of Medtech Insight

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel